Cedric Hermans

Cedric Hermans

Auto-generated profile, based on publicly available information

Cedric Hermans

Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
ADAnne Dompmartin
Anne Dompmartin
FBFanny Ballieux
Fanny Ballieux
PTPascal Thibon
Pascal Thibon
ALAgnès Lequerrec
Agnès Lequerrec
CHCédric Hermans
Cédric Hermans
LBLaurence M. Boon
Laurence M. Boon
Differential diagnosis of vascular malformations can be problematic even in specialized interdisciplinary centers for vascular anomalies because these lesions can mimic each other and some malignant tumors.1,2 The diagnosis is first based on clinical history (presence at birth, growth during life, triggers such as puberty or trauma, and family history) and examination. Important clinical clues are color (variations of pink, red, blue, and purple), aspect (flat, raised, homogeneous, patchy, hyperkeratotic, and ulcerated), localization, size, distribution (unifocal or multifocal), palpation (hard, firm, compressible, and presence of a thrill), temperature (warm or normal), painfulness (spontaneous or provoking factors), and auscultation (bruit). On the basis of these data, an experienced physician can make the diagnosis for most patients.3,4

21 April 2009 in Haemophilia
Verified
Journal Article
Closed access
PDF file
CHC. Hermans
C. Hermans
CAC. Altisent
C. Altisent
ABAngelika Batorova
Angelika Batorova
HCH. Chambost
H. Chambost
PMP. DE Moerloose
P. DE Moerloose
OBOn Behalf Of The European Haemophilia Therapy Standardisation Board
On Behalf Of The European Haemophilia Therapy Standardisation Board

26 March 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
JSJean St‐Louis
Jean St‐Louis
AAAudrey Abad
Audrey Abad
SFSharon Funk
Sharon Funk
MTMerlyn Tilak
Merlyn Tilak
SCStephen Classey
Stephen Classey
BFBrian Michael Feldman
Brian Michael Feldman
The Hemophilia Joint Health Score (HJHS) was developed and validated to detect arthropathy in children. Additional evidence is required to show validity in adults. We studied the convergent and discriminant construct validity of the HJHS version 2.1(HJHSv2.1) in adults with hemophilia. A secondary aim was to define age‐related normative adult HJHSv2.1 reference values. We studied 192 adults with hemophilia, and 120 healthy adults in four age‐matched groups—18 to 29, 30 to 40, 41 to 50, and >50 years—at nine centers. Trained physiotherapists scored the HJHS and World Federation of Hemophilia (WFH) joint score. Health history, the Functional Independence Scale of Hemophilia (FISH), Hemophilia Activities List (HAL), and Short‐Form McGill Pain Questionnaire (SF‐MPQ) were also collected. The median age was 35.0 years. Of participants with hemophilia, 68% had severe, 14% moderate, and 18% mild disease. The HJHS correlated strongly with WFH score (Spearman’s rho [rs ] = .95, P < .001). Moderate correlations were seen between the FISH (rs = .50, P < .001) and SF‐MPQ Present Pain Intensity (rs = .50, P < .001), while a modest correlation was found with the HAL (rs = −.37, P < .001). The HJHS significantly differentiated between age groups (Kruskal‐Wallis T = 35.02, P < .001) and disease severity in participants with hemophilia. The HJHS had high internal reliability (Cronbach’s α = .88). We identified duration of swelling as a redundant item in the HJHS. The HJHS shows evidence of strong convergent and discriminant construct validity to detect arthropathy in adults with hemophilia and is well suited for use in this population.

6 April 2018 in Haemophilia
Verified
Journal Article
Open access
PDF file
JMJohnny Ndoni Mahlangu
Johnny Ndoni Mahlangu
GYG. Young
G. Young
CHC. Hermans
C. Hermans
VBV. Blanchette
V. Blanchette
EBE. Berntorp
E. Berntorp
ESE. Santagostino
E. Santagostino
Introduction: Recent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic (PK) properties that aim to reduce the burden of prophylaxis. These treatments are commonly referred to as extended half‐life rFVIII products (EHL rFVIII). There is no uniform definition of what constitutes an EHL rFVIII. Such a definition would help physicians, patients and funders understand the properties of standard and EHL rFVIIIs and thus provide clarity when selecting an EHL in clinical settings.Aim: To critically assess the published evidence on new and emerging rFVIII products in order to propose a definition to classify EHL rFVIIIs.Methods: We systematically searched PubMed, EMBASE and regulatory authorities (FDA/EMA/Health Canada) websites for publications and regulatory submissions describing prospective crossover PK studies evaluating rFVIIIs that demonstrate improved PK parameters in adults and adolescents with severe haemophilia A.Results: Following critical analyses of the published data, we developed a holistic approach to defining rFVIIIs as EHLs, which requires all of the following: (i) using technology designed to extend rFVIII half‐life; (ii) lacking bioequivalence with a standard rFVIII comparator—above the FDA/EMA cut‐off of 125% for the 90% confidence intervals for area under the curve ratio; and (iii) having an extended half‐life ratio measured in a PK comparator crossover study.Conclusion: In this systematic review, a pragmatic definition of EHL rFVIII has been proposed that should provide better clarity in clinical discussions surrounding the appropriate use of rFVIII products. At present, only products using PEGylation or Fc fusion half‐life extension technology meet the proposed criteria for definition of EHL rFVIII.

1 March 2022 in Blood Reviews
Verified
Journal Article
Open access
CHCedric Hermans
Cedric Hermans
DNDeclan Noone
Declan Noone
GBGary Benson
Gary Benson
GDGerry Dolan
Gerry Dolan
HEHermann Eichler
Hermann Eichler
MMMaria Elisa Mancuso
Maria Elisa Mancuso
The mainstay of hemophilia treatment is to prevent bleeding through regular long-term prophylaxis and to control acute breakthrough bleeds. Various treatment options are currently available for prophylaxis, and treatment decision-making is a challenging and multifaceted process of identifying the most appropriate option for each patient. A multidisciplinary expert panel convened to develop a practical, patient-oriented algorithm to facilitate shared treatment decision-making between clinicians and patients. Key variables were identified, and an algorithm proposed based on five variables: bleeding phenotype, musculoskeletal status, treatment adherence, venous access, and lifestyle. A complementary, patient-focused preference tool was also hypothesized, with the aim of exploring individual patients' priorities, preferences, and goals. It is hoped that the proposed algorithm and the hypothesized patient preference tool will assist in selecting a treatment for each patient that is as efficient as possible in preventing bleeds while also accounting for the patient's expectations and priorities.

1 July 2021 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EKEvelien Krumb
Evelien Krumb
CHCedric Hermans
Cedric Hermans
Despite the numerous and groundbreaking therapeutic advances made in the field of hemophilia over the past decades and particularly in recent years, hemophilia remains a disease that has a major impact on the daily lives of our patients, through the multiple complications and burdensome treatments it imposes. The disease burden is not only physical but also psychological and is difficult to evaluate solely by questionnaires and scores. In this article, we propose to examine the absence of psychological burden and of permanent thoughts about the disease and its complications in people with hemophilia as a new ambition that should guide hemophilia care and research in the future.